Background: A fluorescence spectrometer has been constructed to study in vi
tro and in vivo fluorescence of human lenses. This instrument can measure f
luorescence emission spectra, which can be useful in the characterisation o
f the lens endogenous fluorophores and evaluation of the feasibility of flu
orescence measurement as a non-invasive marker for diabetes. The spectromet
er allows determination of the optimum excitation and emission wavelengths,
which can be used in simpler instrumentation for monitoring purposes.
Methods: To eat the application in such studies a homogeneous group of type
II diabetic subjects and normal controls was studied. For each subject the
fluorescence emission spectra was measured using a spectrometer prototype
consisting of a modified slit lamp coupled to a optical multichannel analys
er (OMA). The incorporation of narrow-band filters allows the selection of
three different excitation wavelengths: 404 nm, 436 nm and 485 nm.
Results: With both in vitro and in vivo measurements, no significant differ
ences were found between diabetic and normal lenses concerning the waveleng
th of maximum emission of fluorescence. However, the spectra (lambda(exc)=4
36 nm) between 480 and 550 nm were better defined with diabetic lenses. Usi
ng ratios of fluorescence intensity at two different wavelengths (490/610,
510/610, and 550/610) allows for good discrimination between normal control
s and diabetic patients. The use of ratios largely removes the effects due
to attenuation of excitation light and emitted fluorescence.
Conclusions: The non-invasive evaluation of lens fluorescence is proposed a
s early indicator of ocular complications associated with diabetes.